Quotient Sciences Quotient Sciences

X
[{"orgOrder":0,"company":"Vitiprints","sponsor":"Tetra BioPharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LakePharma and NJ Bio to streamline antibody-drug conjugate services","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Phase II"}]

Find Clinical Drug Pipeline Developments & Deals by Vitiprints

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Agreement secures a 2D patented printing technology from Vitiprints that will significantly boost production capacity and reduce production costs.

            Lead Product(s): Tetrahydrocannabinol

            Therapeutic Area: Neurology Product Name: CAUMZ

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Tetra BioPharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement February 13, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY